Clonmel Healthcare launch Uzpruvo® (Ustekinumab) – the first approved Ustekinumab biosimilar in Ireland.

Clonmel Healthcare are delighted to announce the introduction of Uzpruvo®, the new Ustekinumab biosimilar. Uzpruvo® will be marketed from July 22^nd 2024, upon expiry of patent protection of the active ingredient of the reference biological medicine.

Uzpruvo® 45mg and 90mg solution for injection in pre-filled syringe are indicated for the treatment of Plaque Psoriasis, Paediatric Plaque Psoriasis, Psoriatic Arthritis and Crohn’s Disease¹. Uzpruvo® is currently not approved for the treatment of ulcerative colitis indication (since the originator still has exclusivity for this indication).